Safety and Efficacy of Vadadustat Once Daily and Three Times Weekly in Patients With Dialysis-Dependent CKD With Anemia
Open Access
- 4 September 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (11) , 1652-1661
Abstract
Key Points: In this phase 3b, noninferiority trial, vadadustat once daily was noninferior to darbepoetin alfa (DA) in the correction and maintenance of hemoglobin in dialysis-dependent CKD. Vadadustat three times weekly treatment resulted in similar changes in mean hemoglobin levels compared with vadadustat once daily, but was not noninferior to DA. The safety profiles of vadadustat once daily and vadadustat three times weekly were comparable with that of DA. Background: Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for treating anemia in CKD. This study investigated the safety and efficacy of once-daily and three-times-weekly dosing in patients with dialysis-dependent CKD compared with darbepoetin alfa (DA). Methods: This phase 3b, randomized (1:1:1; vadadustat once daily [starting dose: 300 or 450 mg], vadadustat three times weekly [starting dose: 600 or 750 mg], DA), open-label, active-controlled, noninferiority trial included conversion (weeks 0–20) and maintenance (weeks 20–52) periods. Primary and secondary efficacy end points were mean change in hemoglobin from baseline during the primary evaluation period (PEP, weeks 20–26) and secondary evaluation period (weeks 46–52). Other end points included proportion of patients requiring erythropoiesis-stimulating agent (ESA) rescue (hemoglobin <9.5 g/dl or with increases in dose ≥50% or ≥100% in the DA group). Safety end points included treatment-emergent adverse events (AEs) and serious AEs. Results: The least-squares (LS) mean treatment difference between vadadustat once daily and DA from baseline to PEP was −0.27 g/dl (95% confidence interval [CI], −0.55 to 0.01); the lower bound met the noninferiority threshold (−0.75 g/dl). The LS mean treatment difference between vadadustat three times weekly and DA from baseline to PEP was −0.53 g/dl (95% CI, −0.80 to −0.25), which did not meet the lower bound noninferiority threshold. The LS mean change from baseline to the secondary evaluation period between DA and vadadustat once daily was −0.40 (95% CI, −0.79 to −0.02) and for vadadustat three times weekly was −0.42 (95% CI, −0.81 to −0.02). The proportion of patients who received ESA rescue during weeks 2–52 was higher in the DA group than vadadustat groups. Similar treatment-emergent AEs and treatment-emergent serious AEs were observed across groups. Conclusions: Vadadustat once daily, but not three times weekly, was noninferior to DA in the correction and maintenance of hemoglobin in patients with dialysis-dependent CKD converted from an ESA; safety profiles were similar across groups. Clinical Trial registry name and registration number: EudraCT 2019-004851-36/ClinicalTrials.gov identifier: NCT04313153.Keywords
This publication has 25 references indexed in Scilit:
- Daprodustat for the Treatment of Anemia in Patients Undergoing DialysisNew England Journal of Medicine, 2021
- Daprodustat for the Treatment of Anemia in Patients Not Undergoing DialysisNew England Journal of Medicine, 2021
- Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing DialysisNew England Journal of Medicine, 2021
- Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKDNew England Journal of Medicine, 2021
- Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney diseaseKidney International Supplements, 2021
- Anemia management for home dialysis including the new US public policy initiativeKidney International Supplements, 2021
- Burden of Anemia in Chronic Kidney Disease: Beyond ErythropoietinAdvances in Therapy, 2020
- Vadadustat: First ApprovalDrugs, 2020
- Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical ExperienceAdvances in Chronic Kidney Disease, 2019
- Real-World Impact of Cardiovascular Disease and Anemia on Quality of Life and Productivity in Patients with Non-Dialysis-Dependent Chronic Kidney DiseaseAdvances in Therapy, 2017